Stay updated on Safety of Ipilimumab and Nivolumab in Liver Resection Clinical Trial
Sign up to get notified when there's something new on the Safety of Ipilimumab and Nivolumab in Liver Resection Clinical Trial page.

Latest updates to the Safety of Ipilimumab and Nivolumab in Liver Resection Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedThe PRIME-HCC study record is displayed with its protocol document and detailed information about the trial’s design, participants, treatments, and outcomes.SummaryDifference56%

- Check20 days agoChange DetectedThe displayed site revision changes from v3.7.2 to v3.8.0, while the page continues to show a 403 Forbidden error.SummaryDifference0.2%

- Check27 days agoChange DetectedA notice about NIH websites transitioning from the term “artificial intelligence” to “super intelligence” appears above the 403 error page. The study record remains unavailable.SummaryDifference1%

- Check34 days agoChange DetectedThe footer revision changed from v3.7.1 to v3.7.2 while the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check41 days agoChange DetectedThe footer’s site revision changes from v3.7.0 to v3.7.1 while the page continues to display a 403 error.SummaryDifference0.2%

- Check54 days agoChange DetectedThe study details page now displays a 403 Forbidden error instead of the original content. This blocks users from viewing the trial's details and related information.SummaryDifference0.5%

Stay in the know with updates to Safety of Ipilimumab and Nivolumab in Liver Resection Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Safety of Ipilimumab and Nivolumab in Liver Resection Clinical Trial page.